CA3120236A1 - Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake - Google Patents
Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake Download PDFInfo
- Publication number
- CA3120236A1 CA3120236A1 CA3120236A CA3120236A CA3120236A1 CA 3120236 A1 CA3120236 A1 CA 3120236A1 CA 3120236 A CA3120236 A CA 3120236A CA 3120236 A CA3120236 A CA 3120236A CA 3120236 A1 CA3120236 A1 CA 3120236A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- administered
- fusion protein
- day
- gdf15
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769675P | 2018-11-20 | 2018-11-20 | |
| US62/769,675 | 2018-11-20 | ||
| PCT/IB2019/059945 WO2020104948A1 (en) | 2018-11-20 | 2019-11-19 | Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3120236A1 true CA3120236A1 (en) | 2020-05-28 |
Family
ID=70773869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3120236A Pending CA3120236A1 (en) | 2018-11-20 | 2019-11-19 | Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220315633A1 (https=) |
| EP (1) | EP3883960A4 (https=) |
| JP (2) | JP2022513098A (https=) |
| KR (1) | KR20210094584A (https=) |
| CN (2) | CN113474363A (https=) |
| AU (2) | AU2019383019A1 (https=) |
| BR (1) | BR112021009225A2 (https=) |
| CA (1) | CA3120236A1 (https=) |
| EA (1) | EA202191424A1 (https=) |
| IL (1) | IL283189A (https=) |
| JO (1) | JOP20210111A1 (https=) |
| MX (1) | MX2021005908A (https=) |
| PH (1) | PH12021551119A1 (https=) |
| SG (1) | SG11202104952PA (https=) |
| WO (1) | WO2020104948A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191105A1 (ru) | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
| EP4041281B1 (en) | 2019-10-04 | 2025-11-26 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9131966B2 (en) * | 2013-03-11 | 2015-09-15 | DePuy Synthes Products, Inc. | Vertebral manipulation assembly |
| EP3157947A1 (en) * | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| JP6946304B2 (ja) * | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| EA202191105A1 (ru) * | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
-
2019
- 2019-11-19 EP EP19886438.1A patent/EP3883960A4/en active Pending
- 2019-11-19 CA CA3120236A patent/CA3120236A1/en active Pending
- 2019-11-19 EA EA202191424A patent/EA202191424A1/ru unknown
- 2019-11-19 AU AU2019383019A patent/AU2019383019A1/en not_active Abandoned
- 2019-11-19 KR KR1020217018694A patent/KR20210094584A/ko active Pending
- 2019-11-19 CN CN201980089716.4A patent/CN113474363A/zh active Pending
- 2019-11-19 MX MX2021005908A patent/MX2021005908A/es unknown
- 2019-11-19 SG SG11202104952PA patent/SG11202104952PA/en unknown
- 2019-11-19 BR BR112021009225-0A patent/BR112021009225A2/pt unknown
- 2019-11-19 CN CN202511010324.8A patent/CN121818901A/zh active Pending
- 2019-11-19 WO PCT/IB2019/059945 patent/WO2020104948A1/en not_active Ceased
- 2019-11-19 US US17/309,328 patent/US20220315633A1/en active Pending
- 2019-11-19 JP JP2021527918A patent/JP2022513098A/ja not_active Withdrawn
-
2021
- 2021-05-13 IL IL283189A patent/IL283189A/en unknown
- 2021-05-14 PH PH12021551119A patent/PH12021551119A1/en unknown
- 2021-05-19 JO JOP/2021/0111A patent/JOP20210111A1/ar unknown
-
2025
- 2025-02-07 JP JP2025019347A patent/JP2025081388A/ja active Pending
- 2025-04-02 AU AU2025202337A patent/AU2025202337A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20210111A1 (ar) | 2021-05-19 |
| CN121818901A (zh) | 2026-04-10 |
| BR112021009225A2 (pt) | 2021-10-05 |
| AU2019383019A1 (en) | 2021-06-03 |
| KR20210094584A (ko) | 2021-07-29 |
| JP2022513098A (ja) | 2022-02-07 |
| EP3883960A4 (en) | 2022-11-09 |
| WO2020104948A1 (en) | 2020-05-28 |
| MX2021005908A (es) | 2021-09-08 |
| PH12021551119A1 (en) | 2021-11-22 |
| AU2025202337A1 (en) | 2025-04-24 |
| US20220315633A1 (en) | 2022-10-06 |
| JP2025081388A (ja) | 2025-05-27 |
| EA202191424A1 (ru) | 2021-08-24 |
| IL283189A (en) | 2021-06-30 |
| EP3883960A1 (en) | 2021-09-29 |
| SG11202104952PA (en) | 2021-06-29 |
| CN113474363A (zh) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3037632T3 (en) | A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia | |
| KR102578030B1 (ko) | 인슐린 글라진／릭시세나티드 고정비 제형 | |
| TW201201832A (en) | Pharmaceutical composition comprising AVE0010 and insulin glargine | |
| JP2025081388A (ja) | 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法 | |
| EA021425B1 (ru) | Мутанты fgf21 и их применение | |
| Briere et al. | Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept | |
| HK1206589A1 (en) | Bche albumin fusions for the treatment of cocaine abuse | |
| KR20220021890A (ko) | 삼중 활성체 지속형 결합체를 유효성분으로 포함하는 약학 조성물 | |
| Majda et al. | Levofloxacin-induced life-threatening hypoglycemia in a type 2 diabetic patient with ST-segment elevation myocardial infarction and community-acquired pneumonia | |
| JP2023544832A (ja) | １型糖尿病の治療および予防のための方法および組成物 | |
| WO2021097407A2 (en) | Novel peptide compositions and methods of treating neurological injury | |
| US20240390464A1 (en) | Treatment of Adults With Overweight or Obesity With or Without Weight-Related Comorbidities | |
| US20250057829A1 (en) | Inhibitors of trpc6 for treating focal segmental glomerulosclerosis | |
| KR20250019690A (ko) | 요법을 위한 gcg/glp1 공동-효능제의 사용 방법 | |
| WO2023245543A1 (en) | Uses of fgf21 fusion proteins | |
| KR20260005268A (ko) | 당뇨병 치료 | |
| TW202140061A (zh) | 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑 | |
| TW202135852A (zh) | 用於治療肥胖症之使用升糖素和glp-1共促效劑之組合療法 | |
| WO2019032469A1 (en) | TREATMENT OF OVERWEIGHT AND OBESITY ASSOCIATED WITH LEPTIN IMPAIRMENT | |
| JP2021528424A (ja) | 対象における食後のグルコースレベルをコントロールする方法および使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231115 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250430 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250430 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250707 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED Effective date: 20251105 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251114 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251127 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251223 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251223 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251223 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260106 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260128 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260128 |